Skip to main content

Table 3 Base-line clinical and behavioral characteristics of DR-TB patients on second anti-TB drugs in Amhara Regional State public hospitals, Ethiopia, September 2010 to December 2017, (N = 570)

From: Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study

Variables

Frequency

Percent (%)

Functional status

 Working

199

35.35

 Ambulatory

172

48.31

 Bedridden

92

16.34

Second line regimen

 E-Z-Cm-Lfx-Eto-Csa

105

18.42

 Z-Cm-Lfx-Eto-Cs

65

11.40

 Z-Cm-Lfx-Pto-Cs

400

70.18

HIV co-infection

 Negative

416

72.98

 Positive

154

27.02

Baseline hemoglobin

 Anemic

212

37.19

 Not anemic

358

62.81

Baseline body mass index(kg/m2)

  < 18.5

402

74.86

 18.5–24.9

135

24.14

Comorbid conditions

 Yes

84

14.74

 No

486

85.26

Type of TB

 Pulmonary

502

88.07

 Extra-pulmonary

44

7.72

 Disseminated

24

4.21

History of smoking

 Yes

77

13.51

 No

493

86.49

History of alcohol drinking

 Yes

86

15.19

 No

480

84.81

Drug abuse

 Yes

27

4.76

 No

540

95.24

  1. aE Ethambutol, Lfx Levofloxacin, Cm Capreomycin, Eto Ethionamide, Pto Protionamide, Cs Cycloserine, Z Pyrazinamide